Abstract:
Mineral and bone disorders in chronic kidney disease (CKD-MBD) are
among the most common and severe complications in patients with renal insufficiency.
Fibroblast Growth Factor 23 (FGF23) is an osteocytic hormone that regulates phosphate
metabolism and vitamin D homeostasis. Its levels begin to rise in the early stages of
CKD and have systemic effects on mineral balance. Excessive FGF23 production
disrupts bone mineralization, exacerbates hypophosphatemia, reduces the synthesis of
active vitamin D, and is associated with an increased risk of cardiovascular
complications. Studying the role of FGF23 in the pathogenesis of CKD-MBD is of high
clinical importance for diagnosis, monitoring, and therapeutic strategy selection.
